Media Contact:
Nicole Osmer
nicole@nicoleosmer.com
(650) 454-0504

Tryton Celebrates 250th Implant of Innovative Side Branch Stent System

Company To Exhibit at TCT Conference in San Francisco

Durham, N. C. – Sept 15, 2009 – Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today that the company's Tryton Side Branch Stent has been used in 250 procedures to treat atherosclerotic lesions at a bifurcation in patients with heart disease.

"Bifurcation lesions have presented a challenge for cardiologists since the earliest days of angioplasty," said Prof. David Foley of Beaumont Hospital in Dublin, Ireland (formerly the cardiac catheterization lab director at Thoraxcentre, Rotterdam). "Current approaches to treating these cases entail adaptation of available stents, leading to complexity and increased risk of peri-procedural complications and late restenosis. The Tryton Side Branch Stent offers a straightforward approach to first securing the side branch, while enabling trouble-free stenting of the main vessel using either a drug eluting or bare metal stent.

"Over the past two months, I have subjected the Tryton Stent to robust challenges in complex bifurcations and am happy to state that it has become an important tool for treating my patients with bifurcation lesions."

"We're pleased that the Tryton Side Branch Stent is helping physicians across Europe treat some of the most challenging interventional cases in cardiovascular disease," said J. Greg Davis, president and CEO of Tryton Medical. "We look forward to demonstrating our innovative stent system at TCT later this month."

Tryton at Transcatheter Cardiovascular Therapeutics (TCT) 2009

Tryton Medical will exhibit the Tryton Side Branch Stent System in booth 630 at this year's Transcatheter Cardiovascular Therapeutics (TCT) Conference taking place in San Francisco Sept. 21 through 25, 2009.

About the Tryton Side Branch Stent System

The Tryton Side Branch Stent System is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. These areas of the vascular system are a common location for plaque and are particularly challenging to treat with currently available stent systems. Approximately twenty percent of patients treated for coronary artery disease have diseased bifurcated lesions.

TRYTON MEDICAL, INC.
1000 Park Forty Plaza, Suite 325
Durham, NC 27713

PHONE 919/226.1490
FAX 919/226.1497
info@trytonmedical.com

Tryton's highly deliverable cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

The Tryton Side Branch Stent System demonstrated excellent six-month clinical results in a first-in-man study of the system in 30 patients, with no restenosis occurring in the side branch artery. The stent system has received CE Mark approval in Europe and is not approved in the United States.

About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company's Side Branch Stent System, approved for sale in Europe, is designed to offer a dedicated strategy for treating these challenging cases. The privately held company is backed by Spray Ventures, PTV Sciences, and RiverVest Ventures. For more information please visit www.trytonmedical.com.

# # #